Teza Capital Management LLC Takes Position in Omnicell, Inc. (NASDAQ:OMCL)

Teza Capital Management LLC purchased a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 3,127 shares of the company’s stock, valued at approximately $221,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Arkadios Wealth Advisors raised its holdings in shares of Omnicell by 447.7% during the first quarter. Arkadios Wealth Advisors now owns 6,205 shares of the company’s stock valued at $407,000 after buying an additional 5,072 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in Omnicell by 5.3% during the first quarter. Thrivent Financial for Lutherans now owns 35,148 shares of the company’s stock worth $2,305,000 after purchasing an additional 1,755 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Omnicell during the first quarter worth approximately $1,123,000. Diversified Trust Co bought a new stake in Omnicell during the second quarter worth approximately $343,000. Finally, BNP Paribas Arbitrage SA raised its holdings in Omnicell by 173.8% during the first quarter. BNP Paribas Arbitrage SA now owns 32,464 shares of the company’s stock worth $2,129,000 after purchasing an additional 20,606 shares in the last quarter. 95.79% of the stock is currently owned by institutional investors.

NASDAQ OMCL opened at $68.45 on Wednesday. Omnicell, Inc. has a twelve month low of $54.24 and a twelve month high of $94.85. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of 37.58, a PEG ratio of 3.07 and a beta of 1.01. The firm’s 50 day moving average price is $67.83 and its two-hundred day moving average price is $70.79.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.14. Omnicell had a net margin of 5.42% and a return on equity of 9.21%. The firm had revenue of $199.62 million for the quarter, compared to analysts’ expectations of $182.16 million. During the same period in the previous year, the company posted $0.67 EPS. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. On average, equities research analysts expect that Omnicell, Inc. will post 1.48 earnings per share for the current fiscal year.

In other news, EVP Scott Peter Seidelmann sold 2,125 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $67.70, for a total transaction of $143,862.50. Following the transaction, the executive vice president now directly owns 33,385 shares in the company, valued at approximately $2,260,164.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Randall A. Lipps sold 3,718 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $75.15, for a total transaction of $279,407.70. Following the transaction, the chief executive officer now owns 152,116 shares in the company, valued at $11,431,517.40. The disclosure for this sale can be found here. Insiders own 2.63% of the company’s stock.

Several equities research analysts recently commented on OMCL shares. Piper Sandler dropped their target price on Omnicell from $76.00 to $70.00 and set a “neutral” rating on the stock in a report on Wednesday, July 29th. Craig Hallum decreased their price target on shares of Omnicell from $102.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, July 29th. Stephens assumed coverage on shares of Omnicell in a research report on Monday, July 6th. They issued an “overweight” rating and a $90.00 price target on the stock. Cantor Fitzgerald lifted their price target on shares of Omnicell from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, BidaskClub upgraded shares of Omnicell from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $85.50.

Omnicell Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Further Reading: What does a market perform rating mean?

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.